Hemogenyx Pharmaceuticals annual operating income
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Operating Income Growth & History (HEMO)
Hemogenyx Pharmaceuticals's operating income was −£4.7M for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£4.7M | −£10.0M | — |
| 2024 | 2024-12-31 | £5.4M | −£1.1M | −16.84% |
| 2023 | 2023-12-31 | £6.5M | £10.5M | — |
| 2022 | 2022-12-31 | −£4.0M | −£1.3M | — |
| 2021 | 2021-12-31 | −£2.7M | −£552,368 | — |
| 2020 | 2020-12-31 | −£2.2M | — | — |
Hemogenyx Pharmaceuticals operating income trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's operating income decreased from −£2.2M to −£4.7M, a change of −£2.5M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
reported operating income
TickerStat standardizes operating income reported in company official filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗Community posts
Hemogenyx loss widens on non-cash options charge despite lower underlying spending
Hemogenyx Pharmaceuticals ($HEMO) reported a first-half pretax loss of £6.56 million, widening from £5.01 million. Reported operating costs increased to £6.48 million, but the company attributed most of the rise to a £5.54 million non-cash ...
